churchyard aeras preventing tb-lessons from treatment of ltbi-1-19 11 13
TRANSCRIPT
GJ Churchyard
20th November 2013
Aeras
Thaler lecture
Preventing TB in high burden countries: lessons learnt from treatment of latent
TB infection
Overview
Background
TB preventive therapy Impact on TB control
Durability
MDR TB
Test of cure
Mechanisms of protection
Implications for TB vaccines
Conclusion
Background
• Burden of disease
• Strategies for TB elimination
• Treatment of LTBI
Estimated TB incidence, 2012
Global trends in TB
Incidence Prevalence Mortality
(Global TB report, 2013)
Potential impact of new TB vaccines, diagnostics and drugs in SE Asia
Sou
rce:
L. A
bu
Rad
da
d e
t al, P
NA
S 2
009
William Osler A Canadian Physician in the 1800
“All who mix with tuberculosis patients got infected, but remained
well so long as they took care of themselves and kept the soil in a
condition unfavourable for the growth of the seed.”
Efficacy of IPT
Akolo. 2010, Cochrane review
0.36
0.86
0.86
0.67
0.74
0.81
1.02
0.95
1.0 1.0
TB prevention: Achieving population level impact
• Treatment of latent TB infection
o Community-wide
o HIV clinics
Churchyard GJ, Lewis JJ, Fielding KL,
Vynnycky E, White RG, Grant AD
on behalf of the Thibela TB team
Community-wide isoniazid preventive therapy among gold miners in South
Africa: the Thibela TB study
TB case notification rates <5%/yr by 2001
Driven by silicosis, exacerbated by HIV (~30% in 2000)
Not contained by conventional control measures
Year
1000
2000
3000
4000
5000 HIV Pos HIV Neg
0
Epidemic TB in SA gold mines
TB rate / 100,000 pop
Extraordinary
problem, needing
an extraordinary
intervention
Effectiveness of IPT among HIV-infected miners
(Grant AD, JAMA, 2005)
Time to recurrence by HIV status
3.5 / 100 pyo
8.7 / 100 pyo
• Re-infection accounted for 68% of recurrence
• ARI ~ 10% / year
(N=609, FU = 1.02 years)
(S Charalambous. Int J TUBERC Lung Dis. 2008;12(8):942–948
0.45
0.3
Haller (1999)
Fitzgerald (2000)
Churchyard (2002)
Reference
(Incidence Rate Ratios & 95% CI)
Efficacy of secondary preventive therapy among HIV+ individuals
1.0
0.18
(Churchyard GJ. Infect Dis. 2007;196 (Suppl. 1): S52-62.)
0
500
1000
1500
2000
2500
3000
1954 1957 1960 1963 1966 1969 1972
Community-wide IPT was effective in controlling epidemic TB in Alaska
TB
in
cid
en
ce p
er
100,0
00 p
op
Comstock. Am Rev Respir Dis. 1979;119:827
Thibela TB: interrupting TB transmission
2.5% prevalence of active TB:
89% prevalence of latent TB
Screen entire
population for
active TB
Active disease:
treatment for
active disease
No active
disease:
treatment for
latent infection
Aim
To compare the
effectiveness of
isoniazid preventive therapy (IPT) given on a community-wide basis
to current standard of care on TB among gold miners in South Africa
Methods
Study design
Cluster-randomised intervention study
Cluster defined as all employees & contractors at mine shaft(s) and associated hostels
Hostels Mine shaft
Cluster
Study design Cluster-randomised intervention study
15 clusters:
5,366 11,892
3,025
6,124 6,586 3,665 8,756 6,091 2,279
1,266 5,187 3,200 3,296 9,173 2,690
Study design Cluster-randomised intervention study
15 clusters: 8 intervention and 7 control
5,366 11,892
3,025
6,124 6,586 3,665 8,756 6,091 2,279
1,266 5,187 3,200 3,296 9,173 2,690
Intervention
Intervention offered to entire workforce
TB screening: symptoms and chest X-ray
Persons with suspected TB investigated by
collecting one sputum specimen for microscopy,
culture, speciation & DST
If eligible, 9 months of isoniazid preventive
therapy. Monthly follow-up visits for
dispensing & screening for TB (symptom) &
possible side effects
Intervention follow-up 9 months
Intervention enrolment 3-16 months
Primary outcome measurement 12 months
Final Survey
Baseline Survey
TB episodes: data collection
Study activity timeline Intervention clusters
Nominal follow-up time
Primary outcome measurement 12 months
Final Survey
Baseline Survey
Study activity timeline Control clusters
TB episodes: data collection
Primary endpoint TB incidence (all cases) among employees
measured over 12 months from last person enrolled completing therapy
Fielding et al Contemporary Clinical Trials 2011 32:382-92
Intervention follow-up 9 months
Intervention enrolment 3-16 months
Primary outcome measurement 12 months
Final Survey
Baseline Survey
Nominal follow-up time
Primary outcome measurement 12 months
Intervention
Control
Secondary endpoints: TB prevalence TB prevalence (sputum culture) among a sample of
employees at the end of the study
Fielding et al Contemporary Clinical Trials 2011 32:382-92
Intervention follow-up 9 months
Intervention enrolment 3-16 months
Primary outcome measurement 12 months
Final Survey
Baseline Survey
Nominal follow-up time
Primary outcome measurement 12 months
Intervention
Control
Results
Participant flow Total population
78,744
Intervention clusters 40,981
Control clusters 37,763
Consented 27,126 (66.2%)
Started IPT 23,659 (87.2%)
Ineligible 1,455 TB suspect 2,012 Ineligible for IPT
0%
20%
40%
60%
80%
100%
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16
cum
ula
tive
% o
f cl
ust
er
con
sen
ted
month from start of intervention
Uptake to the intervention
Uptake in first four clusters = 58.0%
Uptake in last four clusters = 78.7%
% population taking IPT by study month
0%
20%
40%
60%
80%
100%
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16
% o
f cl
ust
er
dis
pe
nse
d IP
T p
er
mo
nth
month from start of intervention
TB Person years Rate/100 pyo
Intervention 887 29,352 3.02
Control 856 29,015 2.95
Effectiveness TB incidence
Among employees in the primary outcome measurement
Incidence rate ratio Unadjusted 1.00 (95% CI 0.75-1.34) Adjusted* 0.96 (95% CI 0.76-1.21) *Adjusted for individual level variables gender, age, surface/underground work, and cluster level variables of silicosis and ART prevalences TB case notification rate 12-months prior to cluster enrolment and pre-randomisation strata
TB prevalence: no effect
Among a sample of employees at study end
TB (n) Total (N) Prevalence (%)
Intervention 166 7,049 2.35
Control 119 5,557 2.14
Prevalence rate ratio Unadjusted 1.05 (95% CI 0.60-1.82) Adjusted* 0.98 (95% CI 0.65-1.48) *Adjusted for gender, age, place of work (individual level); silicosis, ART use, TB CNR (cluster level)
TB case notification rates control clusters
TB case notification rates Intervention clusters
Individual-level effect of isoniazid preventive therapy on risk of
tuberculosis in the Thibela TB study
Objective
We investigate the effect of IPT on TB incidence in individuals starting IPT in intervention clusters vs.
individuals in control clusters
Results – flow diagram Baseline survey
(n=15,609, 15 clusters)
Employees
(n=14,005, 15 clusters)
Control clusters
(n=6,397, 7 clusters)
Intervention clusters
(n=7,608, 8 clusters)
Control arm
(n=6,263, 7 clusters)
IPT arm
(Started IPT)
(n=4,646, 8 clusters)
Excluded
Did not start IPT
(n=2,963)
Excluded
TB / IPT
(n=134)
Excluded
Not employees
(n=1,604)
Thibela TB: duration of IPT effect after at least 6 months of IPT at individual level
0
0.5
1
1.5
2
2.5
3
3.5
0-9 m 9-18m >18m
TB in
cid
en
ce p
er
10
0 p
yrs
IPT arm
Control arm86% reduction in TB
incidence during 9m of IPT
(Fielding CROI 2012)
Reactivation vs. reinfection
Cure, no reinfection Reactivation, no reinfection
Reactivation & reinfection Cure, reinfection
Placebo
6H
Cu
mu
lati
ve in
cid
en
ce
Impact of TB screening on TB incidence among 480 HIV-infected SA gold miners TB screen
Symptoms
CXR
Sputum microscopy and culture (x2)
TB prevalence: 3.3%
TB incidence: 2.6 per 100 pyo
IRR: 1.1
-12 months 12 months Prospective FU Retrospective FU
(Corbett et al. Am J Respir Crit Care Med. 2004,
Lewis et al. Am J Respir Crit Care Med. 2010)
TB Incidence rates following screening
Rates/100py 95% CI
HIV negative < 6 months 0.87 0.34 – 1.96
>6 months 1.83 0.87 – 3.83
HIV positive < 6 months 5.68 3.36 – 9.58
> 6 months 6.70 3.61 – 12.45
Thibela TB: duration of IPT effect after at least 6 months of IPT at individual level
0
0.5
1
1.5
2
2.5
3
3.5
0-9 m 9-18m >18m
TB in
cid
en
ce p
er
10
0 p
yrs
IPT arm
Control arm86% reduction in TB
incidence during 9m of IPT
(Fielding CROI 2012)
Reactivation
Thibela TB: duration of IPT effect after at least 6 months of IPT at individual level
0
0.5
1
1.5
2
2.5
3
3.5
0-9 m 9-18m >18m
TB in
cid
en
ce p
er
10
0 p
yrs
IPT arm
Control arm86% reduction in TB
incidence during 9m of IPT
(Fielding CROI 2012)
Reinfection
0
2000
4000
6000
8000
-1 0 1 2 3 4
Control
Intervention
Years since the introduction of IPT
Allowing model to assume 6m IPT might not cure
Nu
mb
er
of
cases/1
00,0
00 p
yrs
(measu
red
in
cid
en
ce)
Assuming 6m IPT cures latent infections
To match no effect observed, model needed to assume 6 months IPT did not cure latent infections
Best–fitting: % cured= 0%
0
2000
4000
6000
8000
-1 0 1 2 3 4
Dynamic Persistence of Antibiotic-Stressed Mycobacteria
(Wakamoto, Science, 2013))
Even if optimally implemented, community-wide IPT for 9 months would not be a long term solution to TB control in mines
Thibela TB: lack of IPT durability undermines intervention effect
Num
ber
of
ca
se
s/1
00
,000
/ye
ar
(tru
e in
cid
en
ce)
0
1000
2000
3000
4000
No intervention
Optimised IPT
implementation
Thibela TB: summary Community-wide IPT among gold miners
─ At the individual level reduced TB incidence
─ At the population level did not improve TB control
The effect of IPT was not durable due to ─ High rate of reinfection
─ Failure to cure latent infection
Continuous targeted IPT is required to durably reduce risk of TB in high transmission settings
%
reduction HR (95% CI) p-value
Primary Analysis
TB 475 0.87 (0.69-1.10) 0.24
TB/Death 1313 0.74 (0.64-0.85) < 0.001
IPT promotion in 29 HIV clinics in Rio de Janeiro,
Brazil reduced TB incidence/death at a clinic-level
TB incidence during and following IPT
CROI 2013; 190LB
CROI 2013; 190LB
TB incidence during and following IPT
non-completers
Completers
Results: 5-Year Durability
54
0
1
2
3
4
0
5
10
15
20
0 1 2 3 4 5
Po
pu
lati
on
TB
/HIV
Mo
rtal
ity,
pe
r 1
00
,00
0/y
r
Po
pu
lati
on
TB
/HIV
Inci
de
nce
, p
er
10
0,0
00
/yr
Year Since Initial Roll-Out
No IPT
IPT
IPT: 15.6% reduction
IPT: 14.3% reduction
Incidence
Mortality
(Annual rate of IPT delivery: 20%/year to fit study data)
(David Dowdy, Union Conference 2012)
TB preventive therapy
Durability
6-months IPT has limited durability in PWHIV in pre-ART era
6-months IPT has limited durability in PWHIV in pre-ART era
6 months IPT (6H)
36 months IPT (36H)
3 year randomized
controlled trial
Follow-up observation
average 2.7 years/pt
Isoniazid
ART
Increasing ART initiation Antiretroviral therapy
TB rates increase soon after stopping IPT 6H vs 36H in PWHIV in Botswana
0%
3%
6%
9%
0 200 400 600 800 1000
Days after enrolment
Cu
mu
lati
ve
TB
in
cid
en
ce
6H 36H
In-trial n=468
6H 36H
TB rates increase soon after stopping IPT 6H vs 36H in PWHIV in Botswana
TST positive participants
0%
3%
6%
9%
0 200 400 600 800 1000 1200
Days after trial end
Post-trial (no IPT) n=395
6H 36H
0%
3%
6%
9%
0 200 400 600 800 1000
Days after enrolment
Cu
mu
lati
ve
TB
in
cid
en
ce
6H 36H
In-trial n=468
6H 36H
TB rates increase soon after stopping IPT 6H vs 36H in PWHIV in Botswana
↑ 90%
TST positive participants
Time to TB or death: as treated
Martinson, NEJM 2011
6H
cIPT
TB preventive therapy
Latent TB infection with M/XDRTB
Household contacts of M(X)DR TB patients have increased risk of TB & death
Author Pop MDR TB XDR TB
/ Year Incidence 100 pyo
% DST same
% died
Incidence 100 pyo
% DST same
% died
Vella
/ 2011 a
KZN SA
4.0 43.8 14 3.3 59.4 52
Grandjean
/ 2011 b Lima Peru
2.4 72 - - - -
Becerra
/ 2011 c Lima Peru
1.5 59.7 - 2.9 - -
Households with secondary TB cases, % with≥2 TB cases: a=14.5%, b=26.3%, c=unknown
Author Pop MDR TB XDR TB
/ Year Incidence 100 pyo
% DST same
% died
Incidence 100 pyo
% DST same
% died
Vella
/ 2011 a
KZN SA
4.0 43.8 14 3.3 59.4 52
Grandjean
/ 2011 b Lima Peru
2.4 72 - - - -
Becerra
/ 2011 c Lima Peru
1.5 59.7 - 2.9 - -
Households with secondary TB cases, % with≥2 TB cases: a=14.5%, b=26.3%, c=unknown
Household contacts of M(X)DR TB patients have increased risk of TB & death
Author Pop MDR TB XDR TB
/ Year Incidence 100 pyo
% DST same
% died
Incidence 100 pyo
% DST same
% died
Vella
/ 2011 a
KZN SA
4.0 43.8 14 3.3 59.4 52
Grandjean
/ 2011 b Lima Peru
2.4 72 - - - -
Becerra
/ 2011 c Lima Peru
1.5 59.7 - 2.9 - -
Households with secondary TB cases, % with≥2 TB cases: a=14.5%, b=26.3%, c=unknown
Household contacts of M(X)DR TB patients have increased risk of TB & death
Author Pop MDR TB XDR TB
/ Year Incidence 100 pyo
% DST same
% died
Incidence 100 pyo
% DST same
% died
Vella
/ 2011 a
KZN SA
4.0 43.8 14 3.3 59.4 52
Grandjean
/ 2011 b Lima Peru
2.4 72 - - - -
Becerra
/ 2011 c Lima Peru
1.5 59.7 - 2.9 - -
Households with secondary TB cases, % with≥2 TB cases: a=14.5%, b=26.3%, c=unknown
Household contacts of M(X)DR TB patients have increased risk of TB & death
There is a lack of evidence to support use of existing TB drugs for treatment of LTBI with
MDR TB
Potential to use new TB drugs for treating DR LTBI
TB preventive therapy
Mechanisms of protection
Possible mechanisms of protection
Latently infected
person
Possible mechanisms of protection Reduce bacterial burden
Rapid rebound after stopping INH
Rapid rebound after stopping 6H in TST+ Botswanans
Reduced bacterial
burden
Possible mechanisms of protection Reduce bacterial burden
Rapid rebound after stopping INH
Cure, resulting in durable protection 12H in HIV-infected persons in America’s
Cured LTBI (Gordin JAMA 2000)
Possible mechanisms of protection Reduce bacterial burden
Rapid rebound after stopping INH
Cure, resulting in durable protection 12H in Alaskan households
12H in HIV-infected persons in America’s
Prevent reinfection Molecular epidemiology data and high
ARI suggests in high burden settings suggest that the risk of reinfection may be large
Continuous IPT provided durable protection in Botswana and South Africa
Protect against
reinfection
TB free survival in BCG vaccinated infants living with HIV
(Madhi, NEJM, 2011)
Durability post IPT high vs. low burden settings
High transmission settings Low transmission settings
Durability post IPT high vs. low burden settings
High transmission settings Low transmission settings
Durability post IPT high vs. low burden settings
High transmission settings Low transmission settings
High transmission settings Low transmission settings
Durability post IPT high vs. low burden settings
High transmission settings Low transmission settings
• Reduce transmission through
case finding and treatment
• Continuous IPT
• Better regimens
Durability post IPT high vs. low burden settings
High transmission settings Low transmission settings
• Reduce transmission through
case finding and treatment
• Continuous IPT
• Better regimens
• Better, shorter regimens
Durability post IPT high vs. low burden settings
TB preventive therapy
Test of cure
Test of LTBI treatment efficacy Tests for latent TB infection (LTBI) (TST & IGRAs) that are
predictive of future TB risk are available
Biomarkers of LTBI treatment efficacy are needed to identify
those cured
those inadequately treated & at high risk of reactivation
A test of LTBI treatment efficacy will be useful in
Managing patients treated for LTBI
Conducting shorter trials of novel LTBI regimens
therapeutic vaccines
Trial of interferon-g as a biomarker of LTBI treatment efficacy
1,659 HIV-uninfected, TST+, ELISPOT+ household contacts enrolled in the Gambia
IFN-g is not a useful biomarker of treatment efficacy in LTBI (Adetifa et al, Am J Respir Crit Care Med, 2013)
Trial of interferon-g as a biomarker of LTBI treatment efficacy
1,659 HIV-uninfected, TST+, ELISPOT+ household contacts enrolled in the Gambia
IFN-g is not a useful biomarker of treatment efficacy in LTBI (Adetifa et al, Am J Respir Crit Care Med, 2013)
Lessons learnt from treatment of LTBI: implication for TB vaccines
Implications for post exposure TB vaccine
? higher bacterial load in HBCs
May need both treatment of LTBI and vaccines
Need to cure existing infection and prevent reinfection
Needs to be effective in HIV-uninfected and infected persons
Need a test of cure of LTBI
reinfection
Conclusion
Conclusion
The risk of HIV associated TB can be reduced by TB preventive therapy
In high burden settings, TB after IPT is likely to be due to reactivation and reinfection
Continuous IPT can provide durable protection from TB regardless of the mechanism
Effective TB vaccines are required to achieve TB elimination